BRILIQUE® (ticagrelor)

BRILIQUE (ticagrelor) is the only P2Y12 inhibitor licensed in combination with aspirin to protect patients with prior MI and a high risk* of atherothrombotic events against subsequent CV events in both the acute and long-term treatment settings†1

*High risk is defined as ≥1 additional atherothrombotic risk factor (age ≥65 years, >1 prior MI, multivessel coronary artery disease, diabetes requiring medication, chronic non-end-stage renal dysfunction)1

BRILIQUE (ticagrelor) 90mg twice daily  in combination with  acetylsalicylic acid (ASA) is indicated for patients with Acute Coronary Syndromes (ACS) for up to 12 months. BRILIQUE (ticagrelor) 90mg twice daily is not indicated for use in patients beyond 12 months. There are limited data on the efficacy and safety of BRILIQUE (ticagrelor) 60mg beyond 3 years of extended treatment

Mode of Action

BRILIQUE (ticagrelor) works via a dual pathway

BRILIQUE (ticagrelor) acts on the platelet and adenosine pathways:

BRILIQUE acts on the platelet pathway (P2Y12) and the adenosine pathway (ENT-1)
BRILIQUE acts on the platelet pathway (P2Y12) and the adenosine pathway (ENT-1)

‖BRILIQUE (ticagrelor) is an ENT-1 (Equilibrative Nucleoside Transporter) adenosine uptake inhibitor, the clinical relevance of which is under investigation.
BRILIQUE (ticagrelor) should be stopped 7 days prior to elective surgery if antiplatelet effect is not desired  CPTP = cyclo-pentyl-triazolo-pyrimidine.

BRILIQUE (ticagrelor) mode of action video